ArticleVaccines2020
Development of a Safe and Highly Efficient Inactivated Vaccine Candidate against Lumpy Skin Disease Virus.
Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 59 citations in OpenAlex.
- Effective inactivated lumpy skin disease vaccine for cattle using a field viral strain and Montanide 206.Archives of virology · 2026Article
- Article
- Diagnostic approach, vaccination and treatment priorities for Lumpy Skin Disease in cattle: lessons from Balkan epidemics to Western Europe re-emergence (2025).Veterinary research communications · 2026Review
- Review
- Comparative performance of bagging and boosting ensemble models for predicting lumpy skin disease with multiclass-imbalanced data.Scientific reports · 2025Article
- A goatpox but not sheeppox heterologous live attenuated vaccines provide complete protection against lumpy skin disease in cattle under experimental conditions.Scientific reports · 2025Article
- A Genome-Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Optimal immunization strategies for Saanen goats against goatpox.BMC veterinary research · 2025Article
- Progress in diagnostic methods and vaccines for lumpy skin disease virus: a path towards understanding the disease.Veterinary research communications · 2025Review
- Class IIa histone deacetylase (HDAC) inhibitor TMP269 suppresses lumpy skin disease virus replication by regulating host lysophosphatidic acid metabolism.Journal of virology · 2025Article
- Which Proteins? The Challenge of Identifying the Protective Antigens for Next-Generation Capripoxvirus Vaccines.Vaccines · 2025Review
- Lumpy skin disease: A growing threat to the global livestock industry.Open veterinary journal · 2025Review
- Replication and Virulence in Cattle of the First Lumpy Skin Disease Virus Isolated in Xinjiang, China (2019).Transboundary and emerging diseases · 2025Article
- The Safety and Efficacy of New DIVA Inactivated Vaccines Against Lumpy Skin Disease in Calves.Vaccines · 2024Article
- Lumpy Skin Disease: Insights into Molecular Pathogenesis and Control Strategies.Veterinary sciences · 2024Review
- Promising antiviral inhibitors against lumpy skin disease: A vetinformatics approach.Open veterinary journal · 2024Article
- Article
- Article
- Potential Inhibitors of Lumpy Skin Disease's Viral Protein (DNA Polymerase): A Combination of Bioinformatics Approaches.Animals : an open access journal from MDPI · 2024Article
- An insight into emergence of lumpy skin disease virus: a threat to Indian cattle.Archives of microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Capripox virus (CaPV)-induced diseases (lumpy skin disease, sheeppox, goatpox) are described as the most serious pox diseases of livestock animals, and therefore are listed as notifiable diseases under guidelines of the World Organisation for Animal Health (OIE). Until now, only live-attenuated vaccines are commercially available for the control of CaPV. Due to numerous potential problems after vaccination (e.g., loss of the disease-free status of the respective country, the possibility of vaccine virus shedding and transmission as well as the risk of recombination with field strains during natural outbreaks), the use of these vaccines must be considered carefully and is not recommended in CaPV-free countries. Therefore, innocuous and efficacious inactivated vaccines against CaPV would provide a great tool for control of these diseases. Unfortunately, most inactivated Capripox vaccines were reported as insufficient and protection seemed to be only short-lived. Nevertheless, a few studies dealing with inactivated vaccines against CaPV are published, giving evidence for good clinical protection against CaPV-infections. In our studies, a low molecular weight copolymer-adjuvanted vaccine formulation was able to induce sterile immunity in the respective animals after severe challenge infection. Our findings strongly support the possibility of useful inactivated vaccines against CaPV-infections, and indicate a marked impact of the chosen adjuvant for the level of protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.